immunotherapy

Ken Lau, PhD, left, and Bob Coffey, MD, have made several important discoveries about colorectal cancer that are aiding the search for new, more effective therapies. (photo by Erin O. Smith)

Colorectal cancer ‘cartography’ reveals an avenue to improved immunotherapy

Vanderbilt University Medical Center researchers have discovered why most colorectal tumors escape detection and destruction by the body’s immune system.

T cells (orange) engage with cancer cells (blue). Halle Borowski, an artist and senior at the College of William and Mary, worked with Drs. Mary Philip and Jess Roetman to create this oil painting, inspired by their research, as part of the Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) Artist-in-Residence program (https://www.artlab-air.com/).

Tumor antigens key to improving cancer immunotherapy: study

Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

Mary Philip, MD, PhD, left, and Michael Rudloff, PhD, found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional. (photo by Anthony Czelusniak)

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Nanoparticles boost anti-cancer immunity

An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

1 2 3 4 5